Infliximab (anti-TNF-alpha)

製品コード：A2019 Batch: A201901

Infliximab (anti-TNF-alpha) is a purified, recombinant DNA-derived chimeric human-mouse IgG monoclonal antibody that consists of mouse heavy and light chain variable regions combined with human heavy and light chain constant regions. Infliximab neutralizes the biological activity of TNF-α by binding with high affinity to the soluble and transmembrane forms of TNF-α, and inhibits or prevents the effective binding of TNF-α with its receptors. MW=144.2 kDa.

製品説明

CAS No.	170277-31-3
Formulation	PBS, pH 7.0 Contains no stabilizers or preservatives
Isotype	Chimeric IgG1
Source	Chimeric (mouse/human)
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Shipping	Shipped under low temperature conditions
Purity	97.9%
Protein concentration	5.00mg/ml
Endotoxin Level	<1EU/mg

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Modeling and therapeutic targeting of inflammation-induced hepatic insulin resistance using human iPSC-derived hepatocytes and macrophages [ Nat Commun, 2023, 14(1):3902]	PubMed: 37400454
Human iPSC-Derived Proinflammatory Macrophages cause Insulin Resistance in an Isogenic White Adipose Tissue Microphysiological System [ Small, 2023, e2203725.]	PubMed: 37104853
c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma [ Front Immunol, 2022, 13:854995]	PubMed: 35359966

人間や獣医の診断であるか治療的な使用のためにでない。